<DOC>
<DOCNO>1051020_business_story_5375541.utf8</DOCNO>
<TEXT>


The Telegraph - Calcutta : Business

 Wockhardt in pink of health

 OUR SPECIAL CORRESPONDENT 

 Mumbai, Oct. 19: Wockhardt today reported a 30 per cent increase in earnings for the second quarter ended September 30. The pharmaceutical companys net profit rose to Rs 69.2 crore compared with Rs 53.2 crore in the corresponding quarter last year. On a stand-alone basis, its total income increased to Rs 260.9 crore from Rs 225.2 crore in the same period last year.

 Wockhardt said the numbers reflected its resilience and global growth story amidst changing undercurrents in the industry. Habil Khorakiwala, chairman, Wockhardt, said, We are fully committed to higher growth over the next five years. It will come organically as well as through acquisitions.

 The company said the US business grew by 41 per cent during July-September period. The company has entered into a strategic alliance with Perrigo, one of the largest players in the US over-the-counter market, for the distribution of famotidine and ranitidine. 

 Lupin profit jumps

 Lupin recorded a 158 per cent rise in net profit for the quarter ended September 30. Net profit increased to Rs 45.2 crore from Rs 17.5 crore in the same quarter last year. While gross revenues increased by 32 per cent to Rs 419 crore (Rs 318 crore), the companys export revenues rose 42 per cent to Rs 185.5 crore (Rs 130.2 crore), driven by a buoyant offtake of its ceftriaxone vials for injection in the US market. 




</TEXT>
</DOC>